Cargando…
Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India
BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (V...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758821/ https://www.ncbi.nlm.nih.gov/pubmed/36528762 http://dx.doi.org/10.1186/s12879-022-07894-2 |
_version_ | 1784852122362183680 |
---|---|
author | Salvi, Sonali Raichur, Priyanka Kadam, Dileep Sangle, Shashikala Gupte, Nikhil Nevrekar, Neetal Patil, Sandesh Chavan, Amol Nimkar, Smita Marbaniang, Ivan Mave, Vidya |
author_facet | Salvi, Sonali Raichur, Priyanka Kadam, Dileep Sangle, Shashikala Gupte, Nikhil Nevrekar, Neetal Patil, Sandesh Chavan, Amol Nimkar, Smita Marbaniang, Ivan Mave, Vidya |
author_sort | Salvi, Sonali |
collection | PubMed |
description | BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (VL) testing among adults (≥ 18 years) who were registered at a publicly funded ART center in western India between 2014 and 2015 and had received second-line ART for at least 6 months. Sociodemographic and clinical characteristics were abstracted from routinely collected programmatic data. Logistic regression evaluated factors associated with VF (defined as VL > 1000 copies/mL). RESULTS: Among 400 participants, median age was 40 years (IQR 34–44), 71% (285/400) were male, and 15% (59/400) had VF. Relative to participants without VF, those with VF had lower median CD4 counts (230 vs 406 cells/mm(3), p < 0.0001), lower weight at first-line failure (49 vs 52 kg, p = 0.003), were more likely to have an opportunistic infection (17% vs 3%, p < 0.0001) and less likely to have optimal ART adherence (71% vs 87%, p = 0.005). In multivariable analysis, VF was associated with opportunistic infection (aOR, 4.84; 95% CI, 1.77–13.24), lower CD4 count (aOR 4.15; 95% CI, 1.98–8.71) and lower weight at first-line failure (aOR, 2.67; 95% CI, 1.33–5.34). CONCLUSIONS: We found second-line VF in about a sixth of participants in our setting, which was associated with nearly fivefold increased odds in the context of opportunistic infection. Weight could be a useful clinical indicator for second-line VF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07894-2. |
format | Online Article Text |
id | pubmed-9758821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-97588212022-12-18 Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India Salvi, Sonali Raichur, Priyanka Kadam, Dileep Sangle, Shashikala Gupte, Nikhil Nevrekar, Neetal Patil, Sandesh Chavan, Amol Nimkar, Smita Marbaniang, Ivan Mave, Vidya BMC Infect Dis Research BACKGROUND: The number of people receiving second-line antiretroviral therapy (ART) has increased as global access to ART has expanded. Data on the burden and factors associated with second-line ART virologic failure (VF) from India remain limited. METHODS: We conducted cross-sectional viral load (VL) testing among adults (≥ 18 years) who were registered at a publicly funded ART center in western India between 2014 and 2015 and had received second-line ART for at least 6 months. Sociodemographic and clinical characteristics were abstracted from routinely collected programmatic data. Logistic regression evaluated factors associated with VF (defined as VL > 1000 copies/mL). RESULTS: Among 400 participants, median age was 40 years (IQR 34–44), 71% (285/400) were male, and 15% (59/400) had VF. Relative to participants without VF, those with VF had lower median CD4 counts (230 vs 406 cells/mm(3), p < 0.0001), lower weight at first-line failure (49 vs 52 kg, p = 0.003), were more likely to have an opportunistic infection (17% vs 3%, p < 0.0001) and less likely to have optimal ART adherence (71% vs 87%, p = 0.005). In multivariable analysis, VF was associated with opportunistic infection (aOR, 4.84; 95% CI, 1.77–13.24), lower CD4 count (aOR 4.15; 95% CI, 1.98–8.71) and lower weight at first-line failure (aOR, 2.67; 95% CI, 1.33–5.34). CONCLUSIONS: We found second-line VF in about a sixth of participants in our setting, which was associated with nearly fivefold increased odds in the context of opportunistic infection. Weight could be a useful clinical indicator for second-line VF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07894-2. BioMed Central 2022-12-17 /pmc/articles/PMC9758821/ /pubmed/36528762 http://dx.doi.org/10.1186/s12879-022-07894-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Salvi, Sonali Raichur, Priyanka Kadam, Dileep Sangle, Shashikala Gupte, Nikhil Nevrekar, Neetal Patil, Sandesh Chavan, Amol Nimkar, Smita Marbaniang, Ivan Mave, Vidya Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title | Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title_full | Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title_fullStr | Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title_full_unstemmed | Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title_short | Virological failure among people living with HIV receiving second-line antiretroviral therapy in Pune, India |
title_sort | virological failure among people living with hiv receiving second-line antiretroviral therapy in pune, india |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758821/ https://www.ncbi.nlm.nih.gov/pubmed/36528762 http://dx.doi.org/10.1186/s12879-022-07894-2 |
work_keys_str_mv | AT salvisonali virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT raichurpriyanka virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT kadamdileep virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT sangleshashikala virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT guptenikhil virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT nevrekarneetal virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT patilsandesh virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT chavanamol virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT nimkarsmita virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT marbaniangivan virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia AT mavevidya virologicalfailureamongpeoplelivingwithhivreceivingsecondlineantiretroviraltherapyinpuneindia |